Literature DB >> 16403930

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.

Deepak L Bhatt1, P Gabriel Steg, E Magnus Ohman, Alan T Hirsch, Yasuo Ikeda, Jean-Louis Mas, Shinya Goto, Chiau-Suong Liau, Alain J Richard, Joachim Röther, Peter W F Wilson.   

Abstract

CONTEXT: Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis.
OBJECTIVE: To determine whether atherosclerosis risk factor prevalence and treatment would demonstrate comparable patterns in many countries around the world. DESIGN, SETTING, AND PARTICIPANTS: The Reduction of Atherothrombosis for Continued Health (REACH) Registry collected data on atherosclerosis risk factors and treatment. A total of 67,888 patients aged 45 years or older from 5473 physician practices in 44 countries had either established arterial disease (coronary artery disease [CAD], n = 40,258; cerebrovascular disease, n = 18,843; peripheral arterial disease, n = 8273) or 3 or more risk factors for atherothrombosis (n = 12,389) between 2003 and 2004. MAIN OUTCOME MEASURES: Baseline prevalence of atherosclerosis risk factors, medication use, and degree of risk factor control.
RESULTS: Atherothrombotic patients throughout the world had similar risk factor profiles: a high proportion with hypertension (81.8%), hypercholesterolemia (72.4%), and diabetes (44.3%). The prevalence of overweight (39.8%), obesity (26.6%), and morbid obesity (3.6%) were similar in most geographic locales, but was highest in North America (overweight: 37.1%, obese: 36.5%, and morbidly obese: 5.8%; P<.001 vs other regions). Patients were generally undertreated with statins (69.4% overall; range: 56.4% for cerebrovascular disease to 76.2% for CAD), antiplatelet agents (78.6% overall; range: 53.9% for > or =3 risk factors to 85.6% for CAD), and other evidence-based risk reduction therapies. Current tobacco use in patients with established vascular disease was substantial (14.4%). Undertreated hypertension (50.0% with elevated blood pressure at baseline), undiagnosed hyperglycemia (4.9%), and impaired fasting glucose (36.5% in those not known to be diabetic) were common. Among those with symptomatic atherothrombosis, 15.9% had symptomatic polyvascular disease.
CONCLUSION: This large, international, contemporary database shows that classic cardiovascular risk factors are consistent and common but are largely undertreated and undercontrolled in many regions of the world.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16403930     DOI: 10.1001/jama.295.2.180

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  313 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

Review 2.  Proteomic and metabolomic profiles in atherothrombotic vascular disease.

Authors:  Roxana Martinez-Pinna; Coral Barbas; Luis Miguel Blanco-Colio; Jose Tunon; Priscila Ramos-Mozo; Juan Antonio Lopez; Olivier Meilhac; Jean-Baptiste Michel; Jesus Egido; José Luis Martin-Ventura
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

3.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

4.  One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.

Authors:  Kim G Smolderen; Alan Bell; Yang Lei; Eric A Cohen; P Gabriel Steg; Deepak L Bhatt; Elizabeth M Mahoney
Journal:  Can J Cardiol       Date:  2010-10       Impact factor: 5.223

Review 5.  Laparoscopic and robot-assisted laparoscopic digestive surgery: Present and future directions.

Authors:  Juan C Rodríguez-Sanjuán; Marcos Gómez-Ruiz; Soledad Trugeda-Carrera; Carlos Manuel-Palazuelos; Antonio López-Useros; Manuel Gómez-Fleitas
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

6.  [Cardiovascular risk in Spanish smokers compared to non-smokers: RETRATOS study].

Authors:  Jaime Fernández de Bobadilla; Verónica Sanz de Burgoa; Patricio Garrido Morales; Esteban López de Sá
Journal:  Aten Primaria       Date:  2011-03-21       Impact factor: 1.137

7.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.

Authors:  Dharam J Kumbhani; Ph Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Shinya Goto; E Magnus Ohman; Yedid Elbez; Piyamitr Sritara; Iris Baumgartner; Subhash Banerjee; Mark A Creager; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2014-02-28       Impact factor: 29.983

8.  Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.

Authors:  Peter A Soden; Sara L Zettervall; Klaas H J Ultee; Bruce E Landon; A James O'Malley; Philip P Goodney; Randall R DeMartino; Shipra Arya; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-08-27       Impact factor: 4.268

9.  Cardiovascular risk in survivors of stroke.

Authors:  Susan P Kopunek; Kathleen M Michael; Marianne Shaughnessy; Barbara Resnick; Eun-Shim Nahm; Jill Whitall; Andrew Goldberg; Richard F Macko
Journal:  Am J Prev Med       Date:  2007-05       Impact factor: 5.043

10.  ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.

Authors:  C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.